City Therapeutics, Inc. Common Stock (NASDAQ:CTY)
| Market Cap | 207.13M-8.0% |
| Revenue (ttm) | 6.49B-22.4% |
| Net Income | 1.80B-1.4% |
| EPS | 0.00 |
| Shares Out | 9.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,155,236.142 |
| Open | 22.17 |
| Previous Close | 18.00 |
| Day's Range | 20.50 - 22.52 |
| 52-Week Range | 20.50 - 23.88 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About CTY
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
$CTY stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CTY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CTY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CTY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CTY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CTY from public contracts
Source: USAspending.gov
CTY Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CTY’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.